Agios Pharmaceuticals (NASDAQ:AGIO) Earns Outperform Rating from Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report report published on Friday, Benzinga reports. Royal Bank of Canada currently has a $55.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on AGIO. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Raymond James restated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Scotiabank raised their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Stock Down 0.1 %

Shares of AGIO opened at $44.83 on Friday. The business has a 50-day simple moving average of $44.62 and a two-hundred day simple moving average of $42.32. Agios Pharmaceuticals has a 52 week low of $20.40 and a 52 week high of $53.28. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of 3.95, a PEG ratio of 0.45 and a beta of 0.75.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Caxton Associates LP lifted its holdings in shares of Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 0.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 314 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after purchasing an additional 540 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $37,000. Finally, Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $40,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.